Search results
Results from the WOW.Com Content Network
The ESMO Clinical Practice Guidelines on Early and Metastatic Breast Cancer cover information on screening, diagnosis, pathology and molecular biology, staging and risk assessment, disease management, monitoring and follow-up, palliative care and the patient perspective.
For HER2-positive, HR-positive MBC, use standard first-line therapy, or endocrine therapy if contraindications. For triple-negative MBC with unknown PD-L1 status, or if PD-L1–positive and immunotherapy unavailable, use single-agent chemotherapy.
Breast cancer treatment depends on several factors and can include combinations of surgery, chemotherapy, radiation, hormone, and targeted therapy. Learn more about how breast cancer is diagnosed and treated in this expert-reviewed summary.
According to a 2018 article, treating triple-positive breast cancer may include using hormone therapy to target hormone receptors, either on its own or alongside drugs to target HER2....
Breast cancer treatment commonly includes various combinations of surgery, radiation therapy, chemotherapy, and hormone therapy. Prognosis and selection of therapy is influenced by clinical and pathology features. Get detailed information about breast cancer in this summary for clinicians.
These NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget disease, phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy.
Experiencing a pathologic complete response (pCR) to neoadjuvant therapy is associated with favorable disease-free survival (DFS) and overall survival (OS) in early-stage breast cancer.